Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Ocugen

Dow Surges 150 Points; US Consumer Sentiment Edges Lower

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 150 points on Friday.

Benzinga

Why Applied Digital Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket

Shares of Applied Digital Corp (NASDAQ:APLD) rose sharply in pre-market trading after the company released its fiscal first-quarter 2026 earnings report on Thursday.

Benzinga

Ocugen Shares Are Trading Higher Monday: What's Going On?

Ocugen, Inc. (NASDAQ:OCGN) shares traded higher on Monday after the company announced a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket

Shares of Alphabet Inc. (NASDAQ:GOOGL) (NASDAQ:GOOG) rose sharply in pre-market trading after a U.S. judge issued a sealed decision in the Google online search monopoly case.

Benzinga

Dow Tumbles Over 1%; Nio Shares Edge Lower After Q2 Results

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 1% on Tuesday.

Benzinga

Nasdaq Down 1%; Signet Jewelers Earnings Top Views

U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 1% on Tuesday.

Benzinga

Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) rose sharply in pre-market trading after the company announced it will receive a $5 million investment from Ocugen as part of a merger with Ocugen’s subsidiary OrthoCelix.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Ocugen (OCGN) Shares Slide Following Merger Agreement: What's Going On?

Shares of Ocugen Inc (NASDAQ:OCGN) are trading lower by more than 8% Monday afternoon. The company earlier announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics in an all-stock deal.

Benzinga

Wall Street Expects These 2 Under-the-Radar Growth Stocks to Outperform

The recent quarterly results of these two growth stocks show that they have significant long-term growth potential.

Barchart

2 Penny Stocks That Wall Street Believes Can Soar Around 292% to 442%

Analysts believe these two penny stocks have outstanding long-term potential.

Barchart

3 Standout Penny Stocks to Watch This April

Investing in penny stocks carries substantial risk, but also offers the potential for significant returns. These penny stocks, all with bullish analyst ratings, have considerable upside potential, according to Wall Street.

Barchart

Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2022

Benzinga

Ocugen's Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 Years

Ocugen Inc (NASDAQ:OCGN) announced the publication of positive pediatric Phase 2/3 study results in children aged 2–18 years for COVID-19 vaccine, Covaxin (BBV152), in The Lancet Infectious Diseases. Covaxin is developed and manufactured by Ocugen's India-based partner Bharat Biotech International Limited. It is under clinical investigation by Ocugen in the U.S. for use…

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2022

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Ocugen Diversifies Its Pipeline With New Cell Therapy Platform

Ocugen Inc (NASDAQ:OCGN) says it is diversifying its pipeline by introducing a Phase 3 cell therapy platform technology called NeoCart (autologous chondrocyte-derived neocartilage). Recently, the FDA granted a Regenerative Medicine Advanced Therapy (RMAT) designation to NeoCart to repair full-thickness lesions of the knee cartilage in adults. NeoCart is a three-dimensional tissue-engineered disc of…

Benzinga

FDA Removes Clinical Hold On Ocugen's COVID Vaccine Trial

The FDA has lifted the clinical hold on Ocugen Inc's (NASDAQ:OCGN) Phase 2/3 trial, OCU-002, for Covaxin (BBV152), a whole virus inactivated COVID-19 vaccine candidate. In April, the agency paused the trials of the shot, Covaxin, after an inspection of a Bharat Biotech facility by the World Health Organization (WHO) revealed deficiencies…

Benzinga

Monitoring Board Gives Positive Recommendation On Ocugen's Eye Disease Gene Therapy Trial

The independent Data and Safety Monitoring Board (DSMB) for Ocugen Inc's (NASDAQ:OCGN) Phase 1/2 trial of OCU400 has recommended that the study proceeds with enrolling additional subjects. The recommendation follows the review of safety data based on dosing to date. OCU400 is the Company's flagship modifier gene therapy candidate for Retinitis Pigmentosa (RP)…

Benzinga

Why Ocugen Shares Are Trading Higher Today

Ocugen Inc (NASDAQ:OCGN) and Bharat Biotech have amended their co-development, supply, and commercialization agreement to expand Ocugen's exclusive territory to include the commercialization of Covaxin in Mexico. This gives Ocugen Covaxin commercialization rights for all of North America. Covaxin can be an ideal vaccination option for Mexico at this pandemic stage. As a whole…

Get all your
news in one place.

100’s of premium titles.
One news app.

The Hindu

Covaxin trials in U.S. put on hold

WHO had announced suspension of the vaccine supplies through UN procurement agencies

Benzinga

FDA Places Clinical Hold On Ocugen's Late-Stage COVID-19 Vaccine Trial

The

Benzinga

Here's Why Ocugen Shares Are Falling

Ocugen Inc (NASDAQ: OCGN) shares are trading lower by 5.86% to $2.73 during Tuesday's pre-market session after the company announced that it was informed by the FDA that the agency placed its Phase 2/3 immuno-bridging and broadening study for COVAXIN, OCU-002, on clinical hold.

Benzinga

FDA Denies Pediatric EUA To Ocugen For Bharat Biotech's COVID-19 Vaccine Covaxin

The FDA has declined to issue an Emergency Use Authorization (EUA) for Covaxin for active immunization to prevent COVID-19 in individuals 2 to 18 years of age. Ocugen Inc (NASDAQ:OCGN) is working with the vaccine's developer, Bharat Biotech of India, to bring Covaxin to the U.S. Related: FDA Lifts Clinical Hold On Ocugen's COVID-19…

Benzinga

Why Ocugen Shares Are Falling

Ocugen Inc (NASDAQ: OCGN) shares are trading lower by 22.8% at $2.54 after the company announced the FDA declined to issue an EUA for COVAXIN for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 2 to 18 years of age.

Benzinga

The Daily Biotech Pulse: Ocugen Faces Regulatory Setback, vTv CEO Quits, Biogen-Eisai Make Headway With Second Alzheimer's Antibody Treatment In Japan

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Recap: Ocugen Q4 Earnings

Ocugen (NASDAQ:OCGN) reported its Q4 earnings results on Friday, February 25, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

1 2

Organisations

World Health Organization

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.